Pancreatic cancer test kit PANCRECAN™

oncologyfor precision medicinefor BRAF mutations

Gastrointestinal (GI) cancers are a group of cancers that affect the GI tract and accessory organs of the digestive system, such as colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer and gastrointestinal stromal tumor (GIST). Different treatment strategies are available for GI cancers depending on the cancer type and disease stage – including surgery, chemotherapy and radiation therapy, which may be employed alone or in-combination in a neoadjuvant or adjuvant set-up. With recent breakthroughs in uncovering the molecular basis of different GI cancers, targeted therapy and immunotherapy have proven effective in treating GI cancer patients with specific genetic biomarkers. Who Is It For  GI cancer patients seeking precision medicine   Patients with recurrent GI cancers  GI cancer patients resistant to targeted therapy   Sample Types Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others) Targets 56 key genes in pancreatic cancer  Comprehensive testing of mutations in KRAS, EGFR, NRAS, BRAF, PIK3A and other related key genes In-depth analysis of deleterious alterations in BRCA1/2 genes to better inform PARP inhibitor therapy decisions  Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers  Identifies potential drug resistance mechanisms  Assesses genetic predisposition to pancreatic cancer  Contact us today to learn more about PANCRECAN™